4.50
전일 마감가:
$4.50
열려 있는:
$4.41
하루 거래량:
70,450
Relative Volume:
0.76
시가총액:
$229.40M
수익:
-
순이익/손실:
$-103.21M
주가수익비율:
-0.9782
EPS:
-4.6001
순현금흐름:
$-26.70M
1주 성능:
+4.65%
1개월 성능:
-22.28%
6개월 성능:
-32.13%
1년 성능:
-72.56%
Engene Holdings Inc Stock (ENGN) Company Profile
명칭
Engene Holdings Inc
전화
(514) 332-4888
주소
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
ENGN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ENGN
Engene Holdings Inc
|
4.50 | 229.40M | 0 | -103.21M | -26.70M | -4.6001 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-18 | 개시 | Piper Sandler | Overweight |
2025-02-14 | 다운그레이드 | UBS | Buy → Neutral |
2024-12-23 | 개시 | H.C. Wainwright | Buy |
2024-11-27 | 개시 | Raymond James | Outperform |
2024-11-18 | 개시 | JMP Securities | Mkt Outperform |
2024-08-28 | 개시 | Oppenheimer | Outperform |
2024-04-22 | 개시 | Wells Fargo | Overweight |
2024-04-15 | 개시 | Guggenheim | Buy |
2024-03-28 | 개시 | UBS | Buy |
2024-03-08 | 개시 | Morgan Stanley | Overweight |
2024-02-20 | 개시 | Leerink Partners | Outperform |
모두보기
Engene Holdings Inc 주식(ENGN)의 최신 뉴스
Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
enGene Expands Team with New Hires, Grants 144,650 Shares in Stock Options - Stock Titan
Strategic Oncology Updates Coming: enGene CEO Headlines Stifel Healthcare Forum - Stock Titan
How the (ENGN) price action is used to our Advantage - news.stocktradersdaily.com
Promising Trajectory and Strong Financial Position Justify Buy Rating for enGene Holdings - TipRanks
enGene Holdings Insider Ups Holding During Year - Yahoo Finance
enGene Holdings Inc.'s (NASDAQ:ENGN) market cap dropped US$33m last week; individual investors who hold 38% were hit as were institutions - Simply Wall St
enGene’s (ENGN) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
enGene (NASDAQ:ENGN) Price Target Lowered to $34.00 at Morgan Stanley - Defense World
Engene stock holds Buy rating, $25 target from H.C. Wainwright - Investing.com
Engene stock holds Buy rating, $25 target from H.C. Wainwright By Investing.com - Investing.com South Africa
enGene Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
enGene Holdings Inc. SEC 10-Q Report - TradingView
enGene Reports Q1 Results: Strong Cash Position Funds Global Trial Expansion - StockTitan
Trading (ENGN) With Integrated Risk Controls - Stock Traders Daily
enGene to Participate in the Leerink Partners Global Healthcare Conference - Business Wire
What Will enGene Reveal? CEO's Upcoming Fireside Chat at Major Healthcare Conference - Stock Titan
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company - ACCESS Newswire
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch (NASDAQ:ENGN) - Seeking Alpha
Financial Contrast: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS) - Defense World
(ENGN) On The My Stocks Page - Stock Traders Daily
Vontobel Holding Ltd. Makes New $69,000 Investment in enGene Holdings Inc. (NASDAQ:ENGN) - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
enGene (NASDAQ:ENGN) Coverage Initiated at Piper Sandler - Armenian Reporter
enGene Holdings GAAP EPS of -$0.38 - MSN
New Strong Buy Stocks for February 19th - Zacks Investment Research
enGene (NASDAQ:ENGN) Now Covered by Piper Sandler - Defense World
Best Momentum Stocks to Buy for February 19th - Yahoo Finance
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of “Buy” by Brokerages - Defense World
Piper Sandler sets $26 target on Engene shares with Overweight rating - Investing.com Australia
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Buy Rating for enGene Holdings: Strategic Positioning and Growth Potential in NMIBC Market - TipRanks
Piper Sandler Initiates Coverage on enGene Holdings With Overweight Rating, $26 Price Target - Marketscreener.com
Piper Sandler sets $26 target on Engene shares with Overweight rating By Investing.com - Investing.com South Africa
Analyzing Ratios: enGene Holdings Inc (ENGN)’s Financial Story Unveiled - The Dwinnex
enGene (NASDAQ:ENGN) Stock Rating Lowered by UBS Group - Defense World
enGene (NASDAQ:ENGN) Downgraded to Neutral Rating by UBS Group - MarketBeat
Sector Update: Health Care -February 14, 2025 at 03:41 pm EST - Marketscreener.com
EnGene Holdings Shares Fall After UBS Downgrade -February 14, 2025 at 02:55 pm EST - Marketscreener.com
UBS Downgrades enGene Holdings to Neutral From Buy, Cuts Price Target to $7 From $34 - Marketscreener.com
enGene downgraded to Neutral from Buy at UBS - TipRanks
(ENGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
enGene Holdings Inc (ENGN) vs. Its Peers: A Comparison - The News Heater
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Where are the Opportunities in (ENGN) - Stock Traders Daily
Cancer Biotech enGene Strengthens Team with $1.9M Equity Package as Bladder Cancer Trial Advances - Stock Titan
ENGNenGene Holdings Inc. Latest Stock News & Market Updates - StockTitan
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) - Business Wire
FY2026 EPS Estimates for enGene Boosted by Leerink Partnrs - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Engene Holdings Inc (ENGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Engene Holdings Inc 주식 (ENGN) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Forbion Growth Opportunities F | 10% Owner |
Sep 30 '24 |
Buy |
6.34 |
341,332 |
2,163,362 |
2,400,791 |
Forbion Growth Opportunities F | 10% Owner |
Sep 27 '24 |
Buy |
5.97 |
41,639 |
248,699 |
2,059,459 |
Forbion Growth Opportunities F | 10% Owner |
Oct 01 '24 |
Buy |
6.44 |
35,279 |
227,158 |
2,436,070 |
Forbion Growth Opportunities F | 10% Owner |
Oct 07 '24 |
Buy |
6.55 |
11,844 |
77,531 |
2,469,833 |
Forbion Growth Opportunities F | 10% Owner |
Oct 02 '24 |
Buy |
6.37 |
10,153 |
64,697 |
2,446,223 |
Forbion Growth Opportunities F | 10% Owner |
Oct 04 '24 |
Buy |
6.54 |
5,997 |
39,242 |
2,457,989 |
Forbion Growth Opportunities F | 10% Owner |
Oct 03 '24 |
Buy |
6.48 |
5,769 |
37,397 |
2,451,992 |
Forbion Growth Opportunities F | 10% Owner |
Oct 08 '24 |
Buy |
6.60 |
800 |
5,278 |
2,470,633 |
Cooper Ronald Harold Wilfred | Chief Executive Officer |
Sep 27 '24 |
Buy |
5.70 |
10,000 |
57,000 |
10,000 |
Glickman Richard M | Director |
May 28 '24 |
Option Exercise |
0.89 |
120 |
107 |
24,675 |
자본화:
|
볼륨(24시간):